PE20160372A1 - Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion - Google Patents
Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacionInfo
- Publication number
- PE20160372A1 PE20160372A1 PE2016000025A PE2016000025A PE20160372A1 PE 20160372 A1 PE20160372 A1 PE 20160372A1 PE 2016000025 A PE2016000025 A PE 2016000025A PE 2016000025 A PE2016000025 A PE 2016000025A PE 20160372 A1 PE20160372 A1 PE 20160372A1
- Authority
- PE
- Peru
- Prior art keywords
- anticholinergic
- corticosteroid
- inhalation
- dry powder
- powder formulation
- Prior art date
Links
- 230000001078 anti-cholinergic effect Effects 0.000 title abstract 2
- 239000003246 corticosteroid Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 abstract 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Reciprocating Pumps (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13176114 | 2013-07-11 | ||
| EP13194763 | 2013-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160372A1 true PE20160372A1 (es) | 2016-05-19 |
Family
ID=51292914
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000280A PE20212110A1 (es) | 2013-07-11 | 2014-07-10 | Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion |
| PE2016000025A PE20160372A1 (es) | 2013-07-11 | 2014-07-10 | Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000280A PE20212110A1 (es) | 2013-07-11 | 2014-07-10 | Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion |
Country Status (35)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011076843A2 (en) | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Combination therapy for copd |
| EP3020394A1 (en) * | 2012-01-25 | 2016-05-18 | CHIESI FARMACEUTICI S.p.A. | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation |
| CN105338960B (zh) * | 2013-07-11 | 2019-06-04 | 奇斯药制品公司 | 用于吸入施用的包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂 |
| GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| US9554992B2 (en) | 2014-06-09 | 2017-01-31 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic |
| TR201407010A2 (tr) | 2014-06-16 | 2015-12-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Vilanterol formülasyonları. |
| JP6600961B2 (ja) * | 2015-03-30 | 2019-11-06 | ブラザー工業株式会社 | 表示制御装置、表示制御方法及び記憶媒体 |
| CA2983427C (en) * | 2015-05-01 | 2024-04-23 | Board Of Regents, The University Of Texas System | Multidrug brittle matrix compositions |
| AR106687A1 (es) * | 2015-11-16 | 2018-02-07 | Chiesi Farm Spa | PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO |
| TWI731891B (zh) | 2015-11-16 | 2021-07-01 | 義大利商吉斯藥品公司 | 含有抗膽鹼劑、皮質類固醇及β-腎上腺素之乾粉配方之製備方法 |
| DE202017007743U1 (de) | 2016-11-10 | 2025-10-16 | Medisca Pharmaceutique Inc. | System zur pharmazeutischen Zubereitung |
| MX379783B (es) * | 2017-05-11 | 2025-03-04 | Chiesi Farm Spa | Proceso para preparar una formulación de polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico. |
| CN119656140A (zh) * | 2017-05-11 | 2025-03-21 | 奇斯药制品公司 | 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法 |
| CN109200034A (zh) * | 2017-06-30 | 2019-01-15 | 正大天晴药业集团股份有限公司 | 一种可吸入干粉形式的组合物及其制备方法 |
| WO2019060595A1 (en) | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
| BR112022004970A2 (pt) * | 2019-09-24 | 2022-08-23 | Chiesi Farm Spa | Formulação de pó seco, processo para preparar uma formulação de pó seco e inalador de pó seco |
| US12029709B2 (en) * | 2022-08-11 | 2024-07-09 | De Motu Cordis Pty Ltd | Inhalable epinephrine formulation |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU226164B1 (en) | 1998-11-13 | 2008-05-28 | Jagotec Ag | Use of magnesium stearate in dry powder compositions suitable for inhalation and compositions suitable for inhalation |
| US20070212422A1 (en) | 1999-11-10 | 2007-09-13 | Manfred Keller | Dry powder for inhalation |
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
| CA2413692C (en) * | 2000-06-27 | 2011-10-18 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| EP2283818B1 (en) * | 2000-11-30 | 2017-08-02 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| DK1386630T3 (da) | 2002-07-31 | 2006-09-11 | Chiesi Farma Spa | Pulverinhalator |
| JO3102B1 (ar) * | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP1944018A1 (en) * | 2007-01-10 | 2008-07-16 | CHIESI FARMACEUTICI S.p.A. | Micronised particles of low-dosage strength active agents for powder formulations for inhalation |
| WO2011076843A2 (en) | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Combination therapy for copd |
| BR112012015334A2 (pt) | 2009-12-23 | 2016-03-15 | Chiesi Farma Spa | terapia combinada para doença pulmonar obstrutiva crônica |
| TR201000681A2 (tr) | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | İnhalasyon yoluyla alınan kuru toz formülasyonları. |
| EP2552424B1 (en) * | 2010-04-01 | 2018-05-09 | Chiesi Farmaceutici S.p.A. | Process for preparing carrier particles for dry powders for inhalation |
| HRP20180488T1 (hr) * | 2010-04-21 | 2018-07-13 | Chiesi Farmaceutici S.P.A. | Postupak priprave čestica sa smanjenim elektrostatičkim nabojem |
| UA107499C2 (uk) * | 2010-06-22 | 2015-01-12 | Chiesi Farm Spa | Склад сухого порошку, який містить антимускариновий засіб |
| EP3020394A1 (en) | 2012-01-25 | 2016-05-18 | CHIESI FARMACEUTICI S.p.A. | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation |
| US9393202B2 (en) | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| CN105338960B (zh) * | 2013-07-11 | 2019-06-04 | 奇斯药制品公司 | 用于吸入施用的包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂 |
-
2014
- 2014-07-10 CN CN201480037266.1A patent/CN105338960B/zh active Active
- 2014-07-10 NZ NZ715797A patent/NZ715797A/en unknown
- 2014-07-10 PE PE2021000280A patent/PE20212110A1/es unknown
- 2014-07-10 SI SI201431806T patent/SI3409270T1/sl unknown
- 2014-07-10 EP EP18178893.6A patent/EP3409270B1/en active Active
- 2014-07-10 CA CA2917752A patent/CA2917752C/en active Active
- 2014-07-10 ES ES18178893T patent/ES2867552T3/es active Active
- 2014-07-10 DK DK19182016.6T patent/DK3569222T3/da active
- 2014-07-10 UA UAA201600204A patent/UA116907C2/uk unknown
- 2014-07-10 RS RS20210320A patent/RS61652B1/sr unknown
- 2014-07-10 TN TN2016000007A patent/TN2016000007A1/en unknown
- 2014-07-10 FI FIEP19182016.6T patent/FI3569222T3/fi active
- 2014-07-10 EP EP19182016.6A patent/EP3569222B1/en active Active
- 2014-07-10 PL PL18178893T patent/PL3409270T3/pl unknown
- 2014-07-10 HU HUE19182016A patent/HUE068270T2/hu unknown
- 2014-07-10 PT PT14747855T patent/PT3019153T/pt unknown
- 2014-07-10 GE GEAP201414032A patent/GEP20186853B/en unknown
- 2014-07-10 AU AU2014289185A patent/AU2014289185B2/en active Active
- 2014-07-10 SG SG11201600110RA patent/SG11201600110RA/en unknown
- 2014-07-10 PL PL14747855T patent/PL3019153T3/pl unknown
- 2014-07-10 KR KR1020217018070A patent/KR102275904B1/ko active Active
- 2014-07-10 HU HUE14747855A patent/HUE039827T2/hu unknown
- 2014-07-10 KR KR1020167000719A patent/KR20160029797A/ko not_active Ceased
- 2014-07-10 HU HUE18178893A patent/HUE053957T2/hu unknown
- 2014-07-10 JP JP2016524826A patent/JP6426167B2/ja active Active
- 2014-07-10 SI SI201432094T patent/SI3569222T1/sl unknown
- 2014-07-10 LT LTEP14747855.6T patent/LT3019153T/lt unknown
- 2014-07-10 EP EP14747855.6A patent/EP3019153B1/en active Active
- 2014-07-10 SI SI201430976T patent/SI3019153T1/sl unknown
- 2014-07-10 HR HRP20241300TT patent/HRP20241300T1/hr unknown
- 2014-07-10 EA EA201690006A patent/EA029125B1/ru unknown
- 2014-07-10 DK DK18178893.6T patent/DK3409270T3/da active
- 2014-07-10 DK DK14747855.6T patent/DK3019153T3/en active
- 2014-07-10 ES ES19182016T patent/ES2986128T3/es active Active
- 2014-07-10 ES ES14747855T patent/ES2699986T3/es active Active
- 2014-07-10 RS RS20181254A patent/RS57799B1/sr unknown
- 2014-07-10 PL PL19182016.6T patent/PL3569222T3/pl unknown
- 2014-07-10 MX MX2016000290A patent/MX2016000290A/es active IP Right Grant
- 2014-07-10 HR HRP20182008TT patent/HRP20182008T1/hr unknown
- 2014-07-10 LT LTEP18178893.6T patent/LT3409270T/lt unknown
- 2014-07-10 LT LTEP19182016.6T patent/LT3569222T/lt unknown
- 2014-07-10 MY MYPI2016000023A patent/MY176176A/en unknown
- 2014-07-10 US US14/327,920 patent/US9402825B2/en active Active
- 2014-07-10 RS RS20241002A patent/RS65951B1/sr unknown
- 2014-07-10 BR BR112015030914-3A patent/BR112015030914B1/pt active IP Right Grant
- 2014-07-10 TW TW103123763A patent/TWI642450B/zh active
- 2014-07-10 PE PE2016000025A patent/PE20160372A1/es unknown
- 2014-07-10 WO PCT/EP2014/064824 patent/WO2015004243A1/en not_active Ceased
-
2016
- 2016-01-07 PH PH12016500043A patent/PH12016500043B1/en unknown
- 2016-01-07 SA SA516370373A patent/SA516370373B1/ar unknown
- 2016-01-07 IL IL243507A patent/IL243507A0/en active IP Right Grant
- 2016-01-08 CL CL2016000028A patent/CL2016000028A1/es unknown
- 2016-05-20 US US15/160,593 patent/US9808422B2/en active Active
-
2018
- 2018-11-01 CY CY181101132T patent/CY1120806T1/el unknown
-
2021
- 2021-03-12 CY CY20211100219T patent/CY1123937T1/el unknown
- 2021-05-06 HR HRP20210704TT patent/HRP20210704T1/hr unknown
-
2023
- 2023-06-01 AR ARP230101391A patent/AR129501A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160372A1 (es) | Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion | |
| IL264413B (en) | Preparations containing fibers obtained electrohydrodynamically for delivering specific doses of active substance to the skin or mucous membrane | |
| CL2015000744A1 (es) | Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer. | |
| UY35210A (es) | Inhibidores de autotaxina | |
| HUE047782T2 (hu) | Gyógyászatilag aktív vegyületek és alkalmazási eljárásaik | |
| EA201690246A1 (ru) | Ингибиторы аутотаксинов, содержащие ядро гетероароматическое кольцо-бензил-амидный цикл | |
| MX2015002669A (es) | Metodos de administracion de tratamiento con pirfenidona. | |
| BR112014017481A8 (pt) | formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação | |
| CO2018005141A2 (es) | Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico | |
| GT201300304A (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
| MX2016006087A (es) | Formulaciones de desintegracion rapida y metodos de uso. | |
| UY35823A (es) | Profármacos de antagonista de nmda | |
| IN2013MU01111A (enExample) | ||
| CL2016000397A1 (es) | Tratamiento contra el cáncer | |
| UY34080A (es) | Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación | |
| CL2016001062A1 (es) | Composiciones y métodos para administración de una enzima a las vías respiratorias de un sujeto | |
| PL3954360T3 (pl) | Preparat farmaceutyczny węglowodanów do zastosowania terapeutycznego | |
| UY36474A (es) | Método para producir liposomas que contienen un ingrediente farmacéutico activo | |
| PT2988782T (pt) | Formas de dosagem para administração oral de substâncias ativas | |
| TH1401007646A (th) | รูปแบบยาเวชภัณฑ์สำหรับการปลดปล่อยส่วนประกอบออกฤทธิ์ (Medicament form for release of active ingredients) | |
| BR112018009811A8 (pt) | processo para preparar uma formulação de pó seco quecompreende um anticolinérgico, um corticosteroide e um beta-adrenérgico | |
| PH12014000105A1 (en) | Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds |